Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, presented late-breaking data for Iqirvo® (elafibranor), Ipsen’s treatment for primary biliary cholangitis (PBC), at American Association for the Study of Liver Diseases (AASLD).
“Over three years, Iqirvo data suggest sustained efficacy and support the safety profile of the medicine,” said Dr. Kowdley. “Importantly, when patients tell me they are less impacted by itch and fatigue — that matters to me as a physician.”
The results come from Ipsen’s open-label extension of the Phase 3 ELATIVE® study. Recently approved by the FDA, EMA, and MHRA, Iqirvo continues to demonstrate remarkable outcomes and may offer a care option for patients who cannot access or undergo liver transplantation.
Read Ipsen’s press release: https://www.ipsen.com/us/press-releases/iqirvo-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-with-improvements-in-fatigue-and-pruritus-2982128/
